KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest Expenses (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Interest Expenses for 18 consecutive years, with $5.2 million as the latest value for Q1 2026.

  • For Q1 2026, Interest Expenses rose 25.61% year-over-year to $5.2 million; the TTM value through Mar 2026 reached $18.3 million, up 8.05%, while the annual FY2025 figure was $17.3 million, 1.58% up from the prior year.
  • Interest Expenses hit $5.2 million in Q1 2026 for Ionis Pharmaceuticals, up from $4.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $5.2 million in Q1 2026 and bottomed at $1.6 million in Q1 2023.
  • Average Interest Expenses over 5 years is $3.5 million, with a median of $4.2 million recorded in 2024.
  • On a YoY basis, Interest Expenses climbed as much as 163.32% in 2023 and fell as far as 24.22% in 2023.
  • Ionis Pharmaceuticals' Interest Expenses stood at $1.7 million in 2022, then skyrocketed by 163.32% to $4.6 million in 2023, then decreased by 8.05% to $4.2 million in 2024, then increased by 15.2% to $4.8 million in 2025, then rose by 6.88% to $5.2 million in 2026.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $5.2 million, $4.8 million, and $4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.